EGFR, c-erbB-2 and ki-67 in NSCLC and preneoplastic bronchial lesions
Meert, A.P.; Martin, B.; Verdebout, J.M.; Feoli, F.; Mascaux, C.; Ninane, V.; Sculier, J.P.
Anticancer Research 26(1a): 135-138
2006
ISSN/ISBN: 0250-7005 PMID: 16475689 Document Number: 604242
Background: The relationships between EGF-R and c-erbB-2 with other factors involved in tumour regulation are not well understood. The aim of this study was to correlate the expression of these markers with tumour proliferation. Materials and Methods: The presence of EGF-R, c-erbB-2 and Ki-67 was evaluated by immunohistochemistry in non-small cell lung cancer (NSCLC) and preneoplastic lesions. Results: Forty-two percent of the tumours were positive for EGF-R, 22% for c-erbB-2 and 97% for Ki-67. No statistically significant correlation was found between EGF-R and Ki-67, EGF-R and c-erbB-2 or between c-erbB-2 and Ki-67. With regards to Ki-67, a significant difference in survival was noted in favour of patients who did not express the marker. In preneoplastic lesions, most of the low-grade lesions showed neither EGF-R nor Ki-67 staining. In contrast, most of the high-grade lesions stained positively for these proteins. Conclusion: EGF-R and c-erbB-2 do not seem to be correlated with Ki-67 in NSCLC.